^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | LY3143921 (CDC7 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A CR-UK Phase I Trial of LY3143921
Excerpt:
...For Phase Ia (dose escalation): Enriched for patients with tumours commonly associated with p53 mutation or loss of function: 1....
Trial ID:
Source:
Title:
A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
Published date:
05/26/2022
Excerpt:
37 pts were evaluable for radiological response with no complete or partial responses seen, and stable disease (SD) was observed in 24 pts (65%). In phase Ia 3 pts achieved long term SD of 1, 2.5 and 3+ years duration. For evaluable pts treated in phase Ib, SD was seen in 8/12 CRC pts, 1/2 sqNSCLC pts and 2/2 pts treated with the intermittent schedule (median duration 15 weeks, range 6-18+). 2 pts remain on-study. Recruitment ceased due to lack of radiological response according to RECIST. Dose-dependent increases in LY3143921 exposure (Cmax & AUC0-24) were seen. LY3143921 is well tolerated, exhibits dose-dependent increases in plasma exposure and demonstrates evidence of target inhibition.
DOI:
10.1200/JCO.2022.40.16_suppl.3103
Trial ID:
